AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
65 hedge funds and large institutions have $57.6M invested in AVEO Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 5 closing their positions.
600% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 5
270% more capital invested
Capital invested by funds: $15.6M → $57.6M (+$42.1M)
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
86% more funds holding
Funds holding: 35 → 65 (+30)
49% more call options, than puts
Call options by funds: $8.43M | Put options by funds: $5.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$9.02M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.52M |
| 3 |
BlackRock
New York
|
+$4.03M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.72M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$363K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$157K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$157K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$107K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$64.9K |
AVEO Hedge Fund Activity: Q2 2020 in Review
65 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2020, worth a combined $57.6M — up 270% from $15.6M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new AVEO positions and 5 closed out — a net gain of 30 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was NEA Management Company, adding an estimated $9.02M. The largest seller was GSA Capital Partners, cutting an estimated $363K.
- 65 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2020, up from 35 in Q1 2020.
- Funds reported $57.6M of AVEO Pharmaceuticals, Inc. stock for Q2 2020, up 270% quarter-over-quarter.
- 35 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2020 and 5 closed out, a net change of +30 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2020 was NEA Management Company, an estimated $9.02M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2020 was GSA Capital Partners, an estimated $363K sold.
Based on aggregated 13F filings for Q2 2020.